Abstract
e14558 Background: With an ever-increasing focus on personalized medicine, all factors known to affect treatment response need to be considered when defining optimal therapy for an individual patient (pt). While the prognostic impact of primary tumor site on CRC outcomes is established, emerging data suggest potential differences in response to biologic therapies. Here we explore the impact of tumor site on BEV efficacy in pts with mCRC. Methods: Analysis of pts enrolled in an Australian prospective multicenter mCRC registry. Pts diagnosed from July 2009 to December 2013 and treated with first line chemotherapy were included. Tumor site was defined as: right colon (RCC) – cecum to transverse, left colon (LCC) – splenic flexure to rectosigmoid, and rectum (RC). Kaplan Meier and Cox models were used for survival analyses. Results: Of 541 pts, 160 (29.6%) had RCC, 201 (37.2%) LCC and 180 (33.3%) RC primaries. Median age was 69, 66 and 63 years respectively (p=0.002). There was no significant difference in pe...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
